Enhancing B-Cell Malignancies-On Repurposing Enhancer Activity towards Cancer

Area of Science:

• Molecular Biology
• Cancer Research
• Immunology

Background:

• B-cell lymphomas and leukemias are significant causes of cancer death, originating from B cells.
• While oncogenes and tumor suppressors are known drivers, non-coding regulatory sequences, like enhancers, are increasingly implicated in B-cell neoplasm pathogenesis.
• Enhancers regulate cell type- and stage-specific gene expression, vital for normal B cell differentiation and antibody production.

Purpose of the Study:

• To review the diverse mechanisms by which enhancers are exploited in malignant B cells.
• To explore how enhancer dysregulation contributes to the development of B-cell cancers.
• To highlight the therapeutic potential of targeting enhancers in B-cell malignancies.

Main Methods:

• Literature review of established and recent research on enhancer function in B cells.
• Analysis of mechanisms including gene translocations, sequence variants, mutations, and viral hijacking.
• Discussion of therapeutic strategies targeting enhancer activity.

Main Results:

• Enhancer activity can be pathologically redirected in B cells, promoting cancerous transformation.
• Mechanisms of enhancer exploitation include oncogene juxtaposition to immunoglobulin loci via translocations, enhancer dysregulation by mutations/variants, and viral enhancer hijacking.
• These dysregulated enhancers contribute to the pathogenesis of B-cell lymphomas and leukemias.

Conclusions:

• Enhancers play a critical role in B-cell development and cancer.
• Understanding enhancer exploitation in malignant B cells is key to deciphering cancer pathogenesis.
• Targeting enhancers represents a promising future direction for novel B-cell cancer therapies.